This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Evidence of central retinal vein occlusion, defined as documented retinal hemorrhage into all four quadrants with dilated veins, or branch retinal vein occlusion, as documented on clinical exam
• Age 18 years or over
• Central macular edema on clinical exam as well as imaging with a central thickness of ≥ 250 microns
• Visual acuity ranging from 20/8000 to 20/40
• Media clarity and patient cooperation sufficient to allow adequate testing utilizing OCT and FA
• No previous treatment that might compromise or confound assessment of the study outcomes
• Ability to speak and read English

Exclusion Criteria:

• Acute illness or cognitive or other impairment that, in the opinion of the investigator, would interfere with study requirements
• Concurrent ocular conditions likely to significantly compromise vision and contribute the macular compromise
• History of grid/focal laser in the study eye
• History of vitreal surgery
• Previous treatment with triamcinolone acetonide in either eye
• Previous use of bevacizumab, pegaptanib, or ranibizumab in either eye
• Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
• History of cerebrovascular accident within 1 year prior to Day 0
• Inability to comply with study or follow-up procedures
• Any cognitive defect as a result of mental disease, previous injury, or disease process that may interfere with interpretation of study results
• Visual acuity better than 20/40
• Pregnancy (positive pregnancy test) or lactation
• Inadequate contraception in premenopausal women